Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

PROSHARES TRUST (ZBIO) Shares Outstanding (Diluted Average): 2023-2025

Historic Shares Outstanding (Diluted Average) for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to $42.2 million.

  • Zenas BioPharma's Shares Outstanding (Diluted Average) rose 447.69% to $42.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year increase of 447.69%. This contributed to the annual value of $13.2 million for FY2024, which is 762.01% up from last year.
  • Zenas BioPharma's Shares Outstanding (Diluted Average) amounted to $42.2 million in Q3 2025, which was up 0.70% from $41.9 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Shares Outstanding (Diluted Average) registered a high of $42.2 million during Q3 2025, and its lowest value of $1.5 million during Q4 2023.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $10.4 million (2024), whereas its average is $18.9 million.
  • Data for Zenas BioPharma's Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 2,589.73% (in 2025) over the last 5 years.
  • Zenas BioPharma's Shares Outstanding (Diluted Average) (Quarterly) stood at $1.5 million in 2023, then skyrocketed by 762.01% to $13.2 million in 2024, then skyrocketed by 447.69% to $42.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $42.2 million in Q3 2025, compared to $41.9 million in Q2 2025 and $41.8 million in Q1 2025.